279 related articles for article (PubMed ID: 26183688)
1. Prediction of thrombo-embolic risk in patients with hypertrophic cardiomyopathy (HCM Risk-CVA).
Guttmann OP; Pavlou M; O'Mahony C; Monserrat L; Anastasakis A; Rapezzi C; Biagini E; Gimeno JR; Limongelli G; Garcia-Pavia P; McKenna WJ; Omar RZ; Elliott PM;
Eur J Heart Fail; 2015 Aug; 17(8):837-45. PubMed ID: 26183688
[TBL] [Abstract][Full Text] [Related]
2. Risk stratification of patients with left atrial appendage thrombus prior to catheter ablation of atrial fibrillation: An approach towards an individualized use of transesophageal echocardiography.
Gunawardene MA; Dickow J; Schaeffer BN; Akbulak RÖ; Lemoine MD; Nührich JM; Jularic M; Sinning C; Eickholt C; Meyer C; Moser JM; Hoffmann BA; Willems S
J Cardiovasc Electrophysiol; 2017 Oct; 28(10):1127-1136. PubMed ID: 28635023
[TBL] [Abstract][Full Text] [Related]
3. Ischemic Stroke in Patients With Hypertrophic Cardiomyopathy According to Presence or Absence of Atrial Fibrillation.
Fauchier L; Bisson A; Bodin A; Herbert J; Spiesser P; Pierre B; Clementy N; Bernard A; Babuty D; Lip GYH
Stroke; 2022 Feb; 53(2):497-504. PubMed ID: 34601900
[TBL] [Abstract][Full Text] [Related]
4. Predictors of atrial fibrillation in hypertrophic cardiomyopathy.
Guttmann OP; Pavlou M; O'Mahony C; Monserrat L; Anastasakis A; Rapezzi C; Biagini E; Gimeno JR; Limongelli G; Garcia-Pavia P; McKenna WJ; Omar RZ; Elliott PM;
Heart; 2017 May; 103(9):672-678. PubMed ID: 27794017
[TBL] [Abstract][Full Text] [Related]
5. Association of CHA
Hjelholt TJ; Johnsen SP; Brynningsen PK; Pedersen AB
J Am Geriatr Soc; 2020 Aug; 68(8):1698-1705. PubMed ID: 32294240
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and safety of direct oral anticoagulants (DOACs) versus vitamin K antagonist (VKA) among patients with atrial fibrillation and hypertrophic cardiomyopathy: a systematic review and meta-analysis.
Rujirachun P; Charoenngam N; Wattanachayakul P; Winijkul A; Owattanapanich W; Ungprasert P
Acta Cardiol; 2020 Dec; 75(8):724-731. PubMed ID: 31558097
[No Abstract] [Full Text] [Related]
7. [Efficacy and safety of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation and hypertrophic cardiomyopathy].
Liu YY; Du X; He L; Hu R; Ning M; Lyu J; Dong JZ; Ma CS
Zhonghua Xin Xue Guan Bing Za Zhi; 2022 Jan; 50(1):62-67. PubMed ID: 35045616
[No Abstract] [Full Text] [Related]
8. Effect of hypertrophic cardiomyopathy on the prediction of thromboembolism in patients with nonvalvular atrial fibrillation.
Tsuda T; Hayashi K; Fujino N; Konno T; Tada H; Nomura A; Tanaka Y; Sakata K; Furusho H; Takamura M; Kawashiri MA; Yamagishi M;
Heart Rhythm; 2019 Jun; 16(6):829-837. PubMed ID: 30503962
[TBL] [Abstract][Full Text] [Related]
9. Stroke risk in hypertrophic cardiomyopathy patients with atrial fibrillation: a nationwide database study.
Hsu JC; Huang YT; Lin LY
Aging (Albany NY); 2020 Nov; 12(23):24219-24227. PubMed ID: 33226371
[TBL] [Abstract][Full Text] [Related]
10. Prediction of incident atrial fibrillation in hypertrophic cardiomyopathy.
Losi MA; Monda E; Lombardi R; Lioncino M; Canciello G; Rubino M; Todde G; Caiazza M; Borrelli F; Fusco A; Cirillo A; Perillo EF; Sepe J; Pacella D; de Simone G; Calabro P; Esposito G; Limongelli G
Int J Cardiol; 2024 Jan; 395():131575. PubMed ID: 37951419
[TBL] [Abstract][Full Text] [Related]
11. Hypertrophic Cardiomyopathy in Patients with Atrial Fibrillation: Prevalence and Associated Stroke Risks in a Nationwide Cohort Study.
Jung H; Yang PS; Sung JH; Jang E; Yu HT; Kim TH; Uhm JS; Kim JY; Pak HN; Lee MH; Lip GYH; Joung B
Thromb Haemost; 2019 Feb; 119(2):285-293. PubMed ID: 30602200
[TBL] [Abstract][Full Text] [Related]
12. TIMI-AF score and cardiovascular events in vitamin K antagonists-naïve outpatients with atrial fibrillation.
Pérez Cabeza AI; Bravo Marques R; Chinchurreta Capote PA; Ruiz Mateas F; Fanola CL; Rosas Cervantes G; González Correa JA; Valle Alberca A; Mesa Prado F; López Tejero S; Ruff CT
Clin Cardiol; 2018 Sep; 41(9):1252-1258. PubMed ID: 30062699
[TBL] [Abstract][Full Text] [Related]
13. Oral anticoagulation after catheter ablation of atrial fibrillation and the associated risk of thromboembolic events and intracranial hemorrhage: A systematic review and meta-analysis.
Romero J; Cerrud-Rodriguez RC; Diaz JC; Rodriguez D; Arshad S; Alviz I; Cerna L; Rios S; Monhanty S; Natale A; Garcia MJ; Di Biase L
J Cardiovasc Electrophysiol; 2019 Aug; 30(8):1250-1257. PubMed ID: 31257677
[TBL] [Abstract][Full Text] [Related]
14. Left ventricular remodeling in hypertrophic cardiomyopathy patients with atrial fibrillation.
Tian H; Cui J; Yang C; Hu F; Yuan J; Liu S; Yang W; Jiang X; Qiao S
BMC Cardiovasc Disord; 2018 Nov; 18(1):207. PubMed ID: 30390664
[TBL] [Abstract][Full Text] [Related]
15. Atrial fibrillation in hypertrophic cardiomyopathy: prevalence, clinical impact, and management.
Garg L; Gupta M; Sabzwari SRA; Agrawal S; Agarwal M; Nazir T; Gordon J; Bozorgnia B; Martinez MW
Heart Fail Rev; 2019 Mar; 24(2):189-197. PubMed ID: 30456592
[TBL] [Abstract][Full Text] [Related]
16. Persistence of left atrial thrombus in patients with hypertrophic cardiomyopathy and atrial fibrillation.
Burczak DR; Scott CG; Julakanti RR; Kara Balla A; Swain WH; Ismail K; Geske JB; Killu AM; Deshmukh AJ; MacIntyre CJ; Ommen SR; Nkomo VT; Gersh BJ; Noseworthy PA; Siontis KC
J Interv Card Electrophysiol; 2024 Jun; 67(4):731-738. PubMed ID: 37715077
[TBL] [Abstract][Full Text] [Related]
17. Atrial fibrillation and thromboembolism in patients with hypertrophic cardiomyopathy: systematic review.
Guttmann OP; Rahman MS; O'Mahony C; Anastasakis A; Elliott PM
Heart; 2014 Mar; 100(6):465-72. PubMed ID: 24014282
[TBL] [Abstract][Full Text] [Related]
18. Hypertrophic Cardiomyopathy Predicts Thromboembolism and Heart Failure in Patients With Nonvalvular Atrial Fibrillation - A Prospective Analysis From the Hokuriku-Plus AF Registry.
Tsuda T; Hayashi K; Kato T; Kusayama T; Nakagawa Y; Nomura A; Tada H; Usui S; Sakata K; Kawashiri MA; Fujino N; Yamagishi M; Takamura M;
Circ J; 2023 Nov; 87(12):1790-1797. PubMed ID: 37866911
[TBL] [Abstract][Full Text] [Related]
19. Cardiovascular outcomes by time-varying New York Heart Association class among patients with obstructive hypertrophic cardiomyopathy: a retrospective cohort study.
Wang Y; Gao W; Han X; Jiang J; Sandler B; Li X; Zema C
J Med Econ; 2023; 26(1):1495-1506. PubMed ID: 37902966
[TBL] [Abstract][Full Text] [Related]
20. Direct oral anticoagulants in patients with hypertrophic cardiomyopathy and atrial fibrillation.
Dominguez F; Climent V; Zorio E; Ripoll-Vera T; Salazar-Mendiguchía J; García-Pinilla JM; Urbano-Moral JA; Fernández-Fernández X; Lopez-Cuenca D; Ajo-Ferrer R; Sanz-Sanchez J; Gomez-Perez Y; López-Garrido MA; Barriales-Villa R; Gimeno JR; Garcia-Pavia P
Int J Cardiol; 2017 Dec; 248():232-238. PubMed ID: 28811092
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
